who make tirzepatide Makes Zepbound: Eli Lilly's Development and FDA Approval Tirzepatide | C225H348N48O68 | CID

2030 (USD BILLION) FIGURE 16 REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET FIGURE 17 INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH FIGURE 18 US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024 FIGURE 19 SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024 FIGURE 20 HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 FIGURE 21 KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD FIGURE 22 GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FIGURE 23 US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024) FIGURE 24 GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESSES FIGURE 25 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 20222024 (USD) FIGURE 26 GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS FIGURE 27 GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS FIGURE 28 GLP-1 AGONISTS MARKET: PORTERS FIVE FORCES ANALYSIS FIGURE 29 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE FIGURE 30 KEY BUYING CRITERIA FOR END USERS FIGURE 31 AI USE CASES IN GLP-1 AGONISTS MARKET FIGURE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT FIGURE 33 ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 20202024 (USD BILLION) FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024) FIGURE 36 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 FIGURE 37 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024 FIGURE 38 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS) FIGURE 39 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE) FIGURE 40 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 FIGURE 41 EV/EBITDA OF KEY VENDORS FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS FIGURE 43 GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS FIGURE 44 NOVO NORDISK A/S: COMPANY SNAPSHOT FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT FIGURE 46 SANOFI: COMPANY SNAPSHOT FIGURE 47 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT FIGURE 49 INNOVENT: COMPANY SNAPSHOT FIGURE 50 ZEALAND PHARMA: COMPANY SNAPSHOT FIGURE 51 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT FIGURE 53 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT FIGURE 54 BIOCON: COMPANY SNAPSHOT FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT FIGURE 56 F

In summary, GLP-1R agonism improves BP through stimulation of natriuresis via Epac2-dependent stimulation of cardiac ANP secretion [640]

Reach out to our Patient Care Team anytime for updates

If someone truly needed to confirm whether semaglutide was present in your blood, the technology exists